The Novavax vaccine is one of three vaccines available in the U.S. for the prevention of COVID-19 and the only one that does not use the relatively new mRNA vaccine technology. Instead, it relies on a traditional virus-blocking technology that’s been used against other diseases.
In early October the U.S. Food and Drug Administration authorized a new booster shot made by the company Novavax. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant,...
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations.
Novavax COVID-19 Vaccine, Adjuvanted is indicated for individuals 12 years of age and older. Novavax's product will be presented in prefilled syringes, and there is one dosage strength (0.5mL) for all authorized uses.
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine.
